Literature DB >> 25244963

Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitis.

James Fung1, Danny Ka-Ho Wong2, Wai-Kay Seto2, Maggie Kopaniszen3, Ching-Lung Lai2, Man-Fung Yuen2.   

Abstract

OBJECTIVES: The objective of this study was to determine factors associated with hepatitis B surface antigen (HBsAg) seroclearance after hepatitis B e-antigen (HBeAg) seroclearance.
METHODS: This is a cohort study of HBeAg-positive patients with HBeAg seroclearance. Factors associated with subsequent HBsAg seroclearance were examined.
RESULTS: A total of 775 patients were included. At 1, 5, 10, 15, 20, and 25 years after HBeAg seroclearance, the HBsAg seroclearance rate was 0.3, 1.3, 3.0, 8.9, 15.7, and 23.6%, respectively. The rate of HBsAg seroclearance was highest in those who underwent spontaneous HBeAg seroclearance and required no treatment afterward (group 1), compared with those who underwent treatment-induced HBeAg seroclearance (group 2), and those who required antiviral therapy after spontaneous HBeAg seroclearance (group 3). At 25 years after HBeAg seroclearance, the HBsAg seroclearance rate was 38.0, 14.9, and 0% in groups 1, 2, and 3, respectively (P<0.001). There was no difference in the rate of HBsAg seroclearance between those who received interferon-based therapy compared with nucleos(t)ide analogs. The median HBV DNA level was similar between those with and without HBsAg seroclearance. The median HBsAg level was significantly lower in those who had HBsAg seroclearance compared with those who did not achieve loss of HBsAg (2.81 vs. 3.52 log IU/ml, respectively, P=0.009). The area under receiver operating characteristic curve for HBsAg at 1 year after HBeAg seroclearance for predicting HBsAg seroclearance was 0.742, with an optimal cutoff of 751 IU/ml.
CONCLUSIONS: Spontaneous HBeAg seroclearance without need for subsequent antiviral therapy was associated with the highest rate of subsequent HBsAg seroclearance. Lower HBsAg levels were also associated with higher chance of HBsAg seroclearance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25244963     DOI: 10.1038/ajg.2014.301

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  6 in total

1.  Understanding the patient population and test utilization for hepatitis B virus testing.

Authors:  Rihwa Choi; Yejin Oh; Seungman Park; Sang Gon Lee; Eun Hee Lee
Journal:  J Clin Lab Anal       Date:  2019-09-30       Impact factor: 2.352

2.  Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study.

Authors:  Young Min Park; Seong Gyu Lee
Journal:  World J Gastroenterol       Date:  2016-11-28       Impact factor: 5.742

3.  Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels.

Authors:  Yuk-Fai Lam; Wai-Kay Seto; Danny Wong; Ka-Shing Cheung; James Fung; Lung-Yi Mak; John Yuen; Chun-Kong Chong; Ching-Lung Lai; Man-Fung Yuen
Journal:  Clin Transl Gastroenterol       Date:  2017-10-26       Impact factor: 4.488

4.  Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy.

Authors:  Tien-Ching Lin; Yen-Cheng Chiu; Hung-Chih Chiu; Wen-Chun Liu; Pin-Nan Cheng; Chiung-Yu Chen; Ting-Tsung Chang; I-Chin Wu
Journal:  World J Gastroenterol       Date:  2018-02-14       Impact factor: 5.742

5.  Traditional Chinese Medicine Syndrome Patterns and Their Association with Hepatitis B Surface Antigen Levels during the Natural History of Chronic Hepatitis B Virus Infection.

Authors:  He-Ping Xie; Zhi-Ping Liu; Jiong-Shan Zhang; Min Dai; Ge-Min Xiao; Wei-Kang Wu; Hong-Zhi Yang
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-02       Impact factor: 2.629

6.  Single-nucleotide polymorphism of rs7944135 (macrophage-expressed gene 1) is associated with hepatitis B surface antigen seroclearance in chronic hepatitis B infection: A cohort study.

Authors:  Lalu Muhammad Irham; Henry Sung-Ching Wong; Dyah Aryani Perwitasari; Wan-Hsuan Chou; Hwai-I Yang; Wei-Chiao Chang
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.